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Efficacy and safety profile of boceprevir- or telaprevir-based 
triple therapy or dual peginterferon alfa-2a or alfa-2b plus 
ribavirin therapy in chronic hepatitis C: the real-world PegBase 
observational study
Alessandra Mangiaa, Graham R. Fosterb, Christoph P. Bergc, Manuela Curescud, Victor De Ledinghene, 
François Habersetzerf, Spilios Manolakopoulosg, Elisa Negrih, George Papatheodoridisi, Silke Ahlersk, 
Marco Castillol, Georgios Bakalosl, Stefan Maussm on behalf of the PegBase Group Investigators
Background The aim of the study was to determine the efficacy and safety of triple therapy with 
a first-generation protease inhibitor (PI; boceprevir, telaprevir) plus peginterferon alfa-2a or -2b 
plus ribavirin, and dual therapy (peginterferon alfa-2a or  -2b plus ribavirin) in patients with 
chronic hepatitis C (CHC) in routine clinical practice.
Methods PegBase was an international, prospective, observational study in which 4441 patients 
with CHC were enrolled in 27 countries. This analysis focuses on results in 4100 treatment-naïve 
and previously treated patients treated with PI-based triple therapy or dual therapy, according to 
the discretion of the investigator and local standards of practice. The primary efficacy outcome 
was sustained virological response after 12-week follow up (SVR12).
Results SVR12 rates in treatment-naïve genotype (G) 1  patients were 56.6% and 62.9% for 
recipients of boceprevir plus peginterferon alfa-2a/ribavirin and boceprevir plus peginterferon 
alfa-2b/ribavirin, respectively, and 65.3% and 58.6% for recipients of telaprevir plus peginterferon 
alfa-2a/ribavirin and telaprevir plus peginterferon alfa-2b/ribavirin, respectively. In previously 
treated patients assigned to these four regimens, SVR12 rates were 43.6%, 48.3%, 60.3% and 56.1%, 
respectively. Among treatment-naïve patients assigned to peginterferon alfa-2a/ribavirin and 
peginterferon alfa-2b/ribavirin, respectively, SVR12 rates were 49.2% and 41.9% in G1 patients, 
75.7% and 83.3% in G2  patients, 65.9% and 65.9% in G3  patients, and 49.7%, and 51.1% in 
G4 patients. The safety and tolerability of dual and triple therapy were consistent with previous 
reports.
Conclusion The efficacy and safety of first-generation PI-based triple-therapy and dual-therapy 
regimens in this real-world cohort were broadly comparable to those of previous studies.
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Introduction
Hepatitis C virus (HCV) is the most common infectious 
cause of chronic liver disease. More than 185 million people 
worldwide are infected with HCV, of whom 350,000 die 
each year [1]. The highest prevalence of chronic hepatitis C 
(CHC) is in Asia, the Middle East and North Africa. Untreated 
CHC can result in cirrhosis, liver failure and hepatocellular 
carcinoma [1]. HCV genotype (G) 1 is the most prevalent 
among HCV genotypes, comprising almost half of all HCV 
infections [2]. Patients with CHC have a 15-30% risk of 
cirrhosis within 20 years [3], while the risk of hepatocellular 
carcinoma for people with cirrhosis is approximately 2-4% per 
year [4]. It has been estimated that HCV infection accounts 
for the loss of over 12,000 disability-adjusted life years 
worldwide [5].
The primary objective of CHC treatment is eradication of 
the virus from the host, usually characterized as a sustained 
virological response (SVR), defined by the absence of detectable 
HCV RNA in the serum 3-6 months after the end of treatment 
(EoT) [1]. Until 2011, the combination of peginterferon alfa and 
ribavirin for 24 or 48 weeks (dual therapy) was the standard of 
care for patients with CHC, and produced an overall SVR rate 
of approximately 40%. SVR rates with interferon-based therapy 
vary according to host and viral factors, such as HCV genotype, 
HCV RNA level, host IL28B genotype and the extent of hepatic 
fibrosis. Since 2011, direct-acting antivirals (DAAs) have been 
available for the treatment of CHC. The first DAAs, boceprevir 
and telaprevir, were inhibitors (PI) of the HCV protease NS 
3/4A and, when added to peginterferon alfa/ribavirin as 
triple therapy, improved SVR rates to approximately 60-70% 
in G1  patients [6,7]. First-generation PI-based triple therapy 
is associated with a higher rate of hematological adverse 
events (AEs), in particular anemia, and potentially severe 
hypersensitivity reactions are common with telaprevir [6-9]. 
While tolerability was an issue, and the costs of treatment made 
DAAs unavailable for many patients, triple therapy became the 
standard of care for patients with G1 infection. Boceprevir 
and telaprevir have since been superseded by next-generation 
DAAs with improved efficacy and tolerability, and with the 
availability of interferon-free combinations of DAAs with 
higher efficacy and broader genotype coverage, these two drugs 
have been withdrawn from the US market [10-12]. However, 
availability and cost considerations mean that many patients 
still do not have access to newer DAAs, so that peginterferon-
based regimens may still be relevant in some countries [11,12].
The PegBase study is an international, prospective, 
observational study that was initiated after the first PIs became 
available in 2011 with the objective of characterizing the 
efficacy and safety of boceprevir-  and telaprevir-based triple 
therapy, as well as dual therapy, in patients with CHC in routine 
clinical practice.
Patients and methods
The PegBase study was a prospective, international cohort 
study in patients with CHC conducted in 27 countries 
(Belgium, Egypt, Estonia, France, Germany, Greece, Hungary, 
Ireland, Italy, Kuwait, Lebanon, Former Yugoslav Republic 
of Macedonia, Morocco, Oman, Pakistan, Portugal, Qatar, 
Romania, Saudi Arabia, Serbia, Sweden, Switzerland, Syrian 
Arab Republic, Taiwan, Turkey, United Arab Emirates and the 
United Kingdom).
Adult patients with untreated or previously treated 
CHC were eligible if they had quantifiable HCV RNA at the 
start of treatment and were prescribed, as part of standard 
care according to local labeling, either dual combination 
therapy with peginterferon alfa-2a or  -2b plus ribavirin, or 
boceprevir-  or telaprevir-based triple therapy incorporating 
peginterferon alfa 2a or 2b plus ribavirin. Patients with 
hepatitis B virus coinfection were excluded. Drug dosages 
and treatment durations were left to the discretion of the 
investigator and were to be determined according to the local 
label and standards of practice. Patients were followed up for 
24 weeks after completion of treatment.
The current analysis includes results from HCV mono-
infected patients who received dual peginterferon alfa/ribavirin 
therapy, and patients with HCV G1 infection who received 
boceprevir- or telaprevir-based triple therapy, and comprised 
the core population. A comprehensive list of exclusion criteria 
used to define the core population for this analysis is shown 
in Supplemental Table  1. The protocol was approved by 
the Independent Ethics Committee or Institutional Review 
Board at each center, and each patient provided written 
informed consent. The trial is registered with clinicaltrials.gov: 
NCT01447446.
Study endpoints
Virological response (VR) was defined as HCV RNA 
<50 IU/mL (dual therapy) or undetectable HCV RNA (triple 
therapy), using a test with a lower limit of detection ≤50 IU/mL. 
The primary endpoint of the study was SVR. When the trial was 
designed, SVR was defined as VR at 24 weeks post-treatment 
(SVR24); however, after the study was initiated, determination 
of SVR at 12 weeks post-treatment (SVR12) became an accepted 
definition for treatment success [13]. Both SVR12 and SVR24 
were obtained and are presented. However, in this real-world 
study, patients who achieved an SVR12 may have been less 
likely to return for an assessment at 24-week follow up. SVR12 
and SVR24 were defined as achievement of a VR ≥70 and 
≥140 days after the day of last treatment. Scheduling of HCV 
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RNA assessments was at the discretion of the local investigator. 
HCV RNA was measured using polymerase chain reaction 
according to standard methods. Secondary endpoints included 
on-treatment VR rates, relapse rates (defined as detectable 
HCV RNA during follow up in recipients of triple therapy or 
HCV RNA ≥50 IU/mL during follow up in recipients of dual 
therapy in patients with an EoT VR) and rates of breakthrough 
(HCV RNA detectable/≥50  IU/mL while still on treatment 
after an initial response), or rebound (≥1-log10 increase in 
HCV RNA over nadir during treatment). Extended rapid VR 
(eRVR) was defined as a VR at weeks 4 and 12 of treatment in 
patients treated with telaprevir and a VR at weeks 8 and 24 in 
patients treated with boceprevir.
VR rates were also presented by fibrosis status. Investigators 
reported the method of assessment (biopsy, noninvasive or 
best guess) and the result of assessment (cirrhosis, transition 
to cirrhosis, no cirrhosis) on the electronic case report 
form (eCRF). For patients with a biopsy result, transition to 
cirrhosis was prespecified in the eCRF as ISHAK stage 5 or 
4 (with nodules or >3 bridges), METAVIR stage 3, Batts and 
Ludwig stage 3, Knodell stage 3 and Scheuer stage 3. Cirrhosis 
was defined as ISHAK stage 6, METAVIR stage 4, Batts and 
Ludwig stage 4, Knodell stage 4 and Scheuer stage 4. In the 
present analysis, cirrhosis and transition to cirrhosis were 
combined into one category. For patients with no documented 
biopsy result, the determination was based either on a 
noninvasive assessment (if documented in the patient record) 
or a “best guess” assessment. In such cases, one of the three 
categories (cirrhosis, transition to cirrhosis and no cirrhosis) 
was reported in the eCRF, based on the investigator’s judgment 
without prespecified definitions.
Safety endpoints included AEs, serious AEs (SAEs), 
laboratory abnormalities and dose modifications of 
peginterferon alfa and ribavirin. AEs were recorded 
continuously. Laboratory (hematological) parameters were 
measured at the discretion of the investigator according to 
local guidelines.
Statistical analysis
For statistical analysis, no hypothesis testing was performed 
and the endpoints were analyzed by descriptive and exploratory 
methods. The planned sample size of 4000 patients included in 
the overall study was based on feasibility considerations and no 
formal sample size calculations were performed. All analyses 
reported here were conducted in the core study population.
VR rates were calculated with 95% confidence intervals, 
based on the normal approximation to the binomial distribution. 
Subgroup analyses were performed by HCV genotype (dual 
therapy only), presence or absence of transition to cirrhosis 
or cirrhosis, host rs12979860 IL28B gene polymorphism, and 
baseline HCV RNA level (≤400,000 or >400,000 IU/mL). For 
patients with missing virological data during the treatment 
period, if the HCV measurements before and after the missing 
measurement both showed VR, the missing measurement 
was assumed to also show VR. Similarly, for patients with a 
missing EoT measurement, if the next available measurement 
post-treatment showed VR, VR was assumed for EoT. In all 
other cases, missing measurements were considered as non-
response.
AEs were categorized according to the Medical Dictionary 
for Drug Regulatory Affairs version  18.1 and expressed as 
the proportion of patients with an AE. Laboratory safety 
variables were converted to SI units if required, with the results 
transformed to a standard reference range to allow comparison 
of results from different laboratories.
Results
A total of 4441  patients were enrolled and followed up 
between 1  September 2011 and 24  July 2015. Of these, 4352 
individuals received at least one dose of study medication and 
were included in the safety population. A total of 252 patients 
in the safety population were excluded from the core 
population (Supplemental Table  2). The core population for 
analysis comprised 4100 patients, of whom 1292 were assigned 
to boceprevir-  or telaprevir-based triple therapy (all infected 
with HCV G1). Baseline characteristics are shown by treatment 
regimen and treatment history for patients receiving triple 
therapy in Table 1 and for treatment-naïve patients receiving 
dual therapy in Table 2.
Among patients assigned to triple-therapy, 70.2% received 
telaprevir and 29.8% boceprevir (Fig. 1). Patient disposition is 
shown in Table 3 and reasons for premature withdrawal from 
treatment are shown in Table 4.
VR in treatment-naïve patients receiving triple therapy
Among treatment-naïve patients assigned to triple therapy, 
SVR12 rates were 56.6% and 62.9% for patients who received 
boceprevir in combination with peginterferon alfa-2a/ribavirin 
and peginterferon alfa-2b/ribavirin, respectively, and 65.3% 
and 58.6% for patients who received telaprevir in combination 
with peginterferon alfa-2a/ribavirin and peginterferon alfa-2b/
ribavirin, respectively (Fig.  2A). Corresponding relapse rates 
in patients evaluable for relapse in these four treatment groups 
were 14.1%, 18.5%, 15.7% and 5.6%, respectively (Fig.  2B), 
whilst breakthrough or rebound occurred in 8.2%, 14.3%, 8.1% 
and 23.1%, respectively, of patients evaluable for breakthrough 
or rebound (Table 5).
An eRVR was achieved by 46.9% and 42.9% of patients 
receiving boceprevir with peginterferon alfa-2a/ribavirin 
and peginterferon alfa-2b/ribavirin, respectively, and 42.8% 
and 37.9% of patients receiving telaprevir with peginterferon 
alfa-2a/ribavirin and peginterferon alfa-2b/ribavirin, 
respectively.
SVR12 rates were consistently higher in non-cirrhotic than 
in cirrhotic patients and in patients with IL28B CC genotypes 
than in those with non-CC genotypes across the four treatment 
groups (Table 6). SVR12 rates also tended to be higher among 
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Table 1 Baseline patient and disease characteristics – triple therapy








Treatment-naïve N=143 N=35 N=285 N=29
Female, n (%) 49 (34) 12 (34) 118 (41) 8 (28)
Race, n (%)
Caucasian/white 130 (91) 33 (94) 256 (90) 29 (100)
Black 5 (3) 1 (3) 11 (4) –
Asian/Oriental 8 (6) 1 (3) 17 (6) –
Other – – 1 (<1) –
Mean age, years (SD) 47.8 (11.0) 48.8 (12.5) 49.4 (11.7) 52.8 (9.7)
Mean body mass index, kg/m2 (SD) 26.3 (4.9) 25.6 (4.9) 25.9 (4.2) 27.2 (4.9)
Mean HCV RNA, log10 IU/mL (SD) 6.1 (0.7) 6.0 (0.8) 6.0 (0.7) 5.8 (0.7)
HCV RNA >400,000 IU/mL, n (%) 111 (78) 27 (79) 212 (74) 20 (69)
Method of assessing liver fibrosis, n (%)
Biopsy 49 (34) 18 (51) 87 (31) 6 (21)
Noninvasive 83 (58) 15 (43) 174 (61) 21 (72)
Not assessed or best guess 11 (8) 2 (6) 24 (8) 2 (7)
Liver fibrosis status, n (%)
Cirrhosis 32 (22) 8 (23) 61 (21) 12 (41)
Transition to cirrhosis 23 (16) 4 (11) 37 (13) 6 (21)
No cirrhosis 88 (62) 23 (66) 187 (66) 11 (38)
IL28B rs12979860 host genotype, n (%)
CC 25/80 (31) 5/15 (33) 29/143 (20) 3/19 (16)
TC 39/80 (49) 8/15 (53) 82/143 (57) 12/19 (63)
TT 16/80 (20) 2/15 (13) 32/143 (22) 4/19 (21)
Median duration of infection, years 20.0 23.0 18.0 12.5
Patients with type 2 diabetes, n (%) 11 (7.7) 2 (5.7) 20 (7.0) 1 (3.4)
Previously treated N=149 N=58 N=536 N=57
Female, n (%) 59 (40) 25 (43) 213 (40) 35 (61)
Race, n (%)
Caucasian/white 143 (96) 55 (95) 515 (96) 57 (100)
Black 2 (1) – 7 (1) –
Asian/Oriental 3 (2) 3 (5) 13 (2) –
Other 1 (<1) – 1 (<1) –
Mean age, years (SD) 54.3 (8.1) 56.9 (9.6) 54.0 (9.5) 57.1 (9.3)
Mean body mass index, kg/m2 (SD) 27.2 (5.0) 26.0 (4.0) 26.7 (4.5) 28.6 (6.4)
Mean HCV RNA, log10 IU/mL (SD) 6.1 (0.7) 6.1 (0.6) 6.1 (0.7) 5.8 (0.8)
HCV RNA >400,000 IU/mL, n (%) 113 (76) 44 (76) 417 (78) 41 (72)
Method of assessing liver fibrosis, n (%)
Biopsy 35 (23) 7 (12) 66 (12) 8 (14)
Noninvasive 91 (61) 42 (72) 367 (68) 42 (74)
Not assessed or best guess 23 (15) 9 (16) 103 (19) 7 (12)
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Table 1 (Continued)








Previously treated N=149 N=58 N=536 N=57
Liver fibrosis status, n (%)
Cirrhosis 56 (38) 18 (31) 156 (29) 14 (25)
Transition to cirrhosis 27 (18) 11 (19) 87 (16) 11 (19)
No cirrhosis 66 (44) 29 (50) 293 (55) 32 (56)
IL28B rs12979860 host genotype, n/N 
(%)
CC 10/82 (12) 5/37 (14) 43/288 (15) 5/42 (12)
TC 51/82 (62) 25/37 (68) 179/288 (62) 27/42 (64)
TT 21/82 (26) 7/37 (19) 65/288 (23) 10/42 (24)
Negative – – 1/288 (<1) –
Median duration of infection, years 21.0 17.0 21.0 8.0
Patients with type 2 diabetes, n (%) 24 (16.1) 10 (17.2) 68 (12.7) 1 (1.8
Response to prior treatment, n (%)
Relapse 44 (30) 19 (33) 177 (33) 27 (48)
Breakthrough 5 (3) 3 (5) 37 (7) 2 (4)
Non-response 82 (55) 28 (48) 248 (47) 17 (30)
Other 17 (11) 7 (12) 68 (13) 10 (18)
Missing 1 (1) 1 (2) 6 (1) 1 (2)
IL28B rs12979860 genotype was known for 257 treatment-naïve patients and 449 treatment-experienced patients; percentages are calculated from those with 
available data. One treatment-experienced patient was negative for rs12979860 
HCV, hepatitis C virus; PegIFN, peginterferon; RBV, ribavirin; SD, standard deviation
patients with low baseline HCV RNA levels (≤400,000 IU/mL), 
although this was not the case in the small number of patients 
with low HCV RNA levels assigned to boceprevir plus 
peginterferon alfa-2a/ribavirin (n=32; Table 6).
VR in previously treated patients receiving triple therapy
SVR12 rates were generally lower in previously treated 
patients than in treatment-naïve patients assigned to the 
same treatment group (Tables  5, 6). Among previously 
treated patients assigned to triple therapy, SVR12 rates were 
43.6% and 48.3% for patients who received boceprevir plus 
peginterferon alfa-2a/ribavirin and peginterferon alfa-2b/
ribavirin, respectively and 60.3% and 56.1% for patients 
who received telaprevir plus peginterferon alfa-2a/ribavirin 
and peginterferon alfa-2b/ribavirin, respectively (Fig.  2C). 
Corresponding relapse rates in these four treatment groups 
were 28.1%, 22.2%, 12.6% and 8.6%, respectively, among 
patients evaluable for relapse (Fig. 2D), whilst breakthrough 
or rebound occurred in 9.2%, 17.0%, 18.7% and 20.8%, 
respectively, of patients evaluable for breakthrough or rebound 
(Table 5).
Consistently with trends observed in treatment-naïve 
patients, SVR12 rates were generally higher among previously 
treated patients who were non-cirrhotic compared to those who 
were cirrhotic, and among those with low baseline HCV RNA 
levels (Table  6). SVR12 rates tended to be higher in patients 
with CC than in those with non-CC genotypes, although the 
number of patients with CC genotypes was very small among 
previously treated patients (i.e., 3 of 4 groups had ≤10 patients) 
and the trend was not observed consistently in all treatment 
groups.
SVR12 rates were generally, but not exclusively, higher in 
patients with a prior relapse than among those with a prior 
breakthrough or non-response (Table 6). When all four triple 
therapy groups were combined, the overall response rates in 
patients with a prior relapse, breakthrough or non-response 
were 73.8% (197/267), 55.3% (26/47) and 44.3% (166/375), 
respectively.
Safety in patients receiving triple therapy
Across the four triple-therapy treatment groups, the overall 
incidence of AEs ranged from 76.7% to 90.7% and the overall 
incidence of SAEs ranged from 4.7% to 19.9% (Table 7). The 
spectrum and frequency of individual AEs was similar to that 
reported previously, with anemia being the most frequently 
reported AE. Safety-related dose modifications were required 
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Previously treated N=348 N=82
Female, n (%) 137 (39) 40 (49)
Race, n (%)
Caucasian/white 313 (90) 73 (89)
Black 4 (1) 2 (2)
Asian/Oriental 30 (9) 7 (9)
Other 1 (<1) –
Mean age, years (SD) 51.6 (11.0) 54.6 (10.6)
Genotype, n (%)
1 173 (49.7) 46 (56.1)
Non-1 175 (50.3) 36 (43.9)
Mean body mass index, 
kg/m2 (SD)
26.5 (4.6) 27.0 (4.5)
Mean HCV RNA,  
log10 IU/mL (SD)
5.9 (0.8) 5.9 (0.7)
HCV RNA >400,000 
IU/mL, n (%)
251 (72.1) 60 (73.2)
Method of assessing 
liver fibrosis, n (%)
Biopsy 34 (10) 6 (7)
Noninvasive 221 (64) 60 (73)
Not assessed or best 
guess
93 (27) 16 (20)
Liver fibrosis status, n (%)
Cirrhosis 76 (22) 15 (18)
Transition to cirrhosis 64 (18) 15 (18)
No cirrhosis 208 (60) 52 (63)
IL28B rs12979860 host 
genotype, n (%)*
CC 69/219 (32) 16/51 (31) 
TC 117/219 (53) 25/51 (49)
TT 33/219 (15) 10/51 (20)
Median duration of 
infection, years
17.0 15.0
Patients with type 2 
diabetes, n (%)
41 (11.8) 13 (15.9)
*One patient assigned to peginterferon alfa-2a plus ribavirin was negative 
for rs12979860  
HCV, hepatitis C virus; PegIFN, peginterferon; RBV, ribavirin; SD, standard 
deviation
Table 2 Baseline patient and disease characteristics of patients 






Female, n (%) 773 (39) 210 (51)
Race, n (%)
Caucasian/white 1709 (87) 370 (89)
Black 29 (1) 2 (<1)
Asian/Oriental 222 (11) 42 (10)
Other 4 (<1) –
Mean age, years (SD) 46.7 (13.0) 49.1 (12.8)
Genotype, n (%)
1 815 (41.5) 198 (47.8)
2 268 (13.6) 78 (18.8)
3 528 (26.9) 91 (22.0)
4 340 (17.3) 45 (10.9)
5 5 (0.3) 1 (0.2)
6 8 (0.4) 1 (0.2)
Mean body mass index, 
kg/m2 (SD)
26.4 (4.5) 25.6 (4.7)
Mean HCV RNA, log10 
IU/mL (SD)
5.8 (0.9) 5.8 (0.9)
HCV RNA >400,000 
IU/mL, n (%)
1305 (66.5) 275 (66.4)
Method of assessing 
liver fibrosis, n/N (%)
Biopsy 442/1963 (23) 84/414 (20)
Noninvasive 1152/1963 (59) 250/414 (60)
Not assessed or best 
guess
369/1963 (19) 80/414 (19)
Liver fibrosis status, 
n/N (%)
Cirrhosis 234/1963 (12) 47/414 (11)
Transition to cirrhosis 265/1963 (13) 55/414 (13)
No cirrhosis 1464/1963 (75) 312/414 (75)
IL28B rs12979860 host 
genotype, n/N (%)a
CC 468/1243 (38) 81/246 (33) 
TC 617/1243 (50) 126/246 (51)
TT 157/1243 (13) 39/246 (16)
Median duration of 
infection, years
12.0 13.0
Patients with type 2 
diabetes, n (%)
179 (9.1) 43 (10.4)
(Contd...)
more frequently for ribavirin (range 36.0% to 46.4%) than 
for peginterferon alfa (range 10.5% to 19.4%) across the four 
treatment groups. Anemia was the most frequently cited 
reason for ribavirin dose modifications, whilst neutropenia 
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was the most frequently cited reason for peginterferon alfa 
dose modifications (Table 7). Approximately 40% of patients 
in each treatment group experienced a hemoglobin level 
<100  g/dL during therapy and approximately 40% to 50% 
of patients experienced a platelet level <100 × 109/L at some 
point during treatment (Table  7). Hepatic failure was rare, 
being reported as an SAE in two patients assigned to telaprevir 
plus peginterferon alfa-2a/ribavirin and as a non-serious AE 
in two additional patients (one assigned to boceprevir plus 
peginterferon alfa-2a/ribavirin, and one assigned to telaprevir 
plus peginterferon alfa-2a/ribavirin). Infections were reported 
as SAEs in 11 of 385 (2.9%) patients assigned to boceprevir-
based triple therapy and in 34 of 907 (3.7%) patients assigned 
to telaprevir-based triple therapy. A  total of 11  patients 
assigned to boceprevir-  or telaprevir-based triple therapy 
died during the study; seven of the deaths were unrelated 
to CHC or treatment. Two deaths were considered to be 
related to CHC and to the study drug in the opinion of the 
investigator; both patients had been assigned to telaprevir plus 
peginterferon alfa-2a (one death was attributed to esophageal 
variceal hemorrhage and the other to hepatic failure). Two 
additional deaths from liver cancer, both in patients assigned 
to telaprevir plus peginterferon alfa-2a, were considered to be 
related to CHC, but not to the study drug.
Figure 1 Disposition of treatment-naïve and previously treated patients with chronic hepatitis C who were enrolled and treated with boceprevir 
(BOC)- or telaprevir (TEL)-based triple therapy or dual peginterferon (PegIFN) alfa-2a or alfa-2b plus ribavirin (RBV). (A) Patients assigned to 
BOC- or TEL-based triple therapy. (B) Patients assigned to dual PegIFN alfa-2a or alfa-2b plus ribavirin therapy
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HCV genotype 1 N=143 N=35 N=285 N=29 N=815 N=198
Completed 12-week 
treatment
130 (90.9) 34 (97.1) 259 (90.9) 26 (89.7) 776 (95.2) 178 (89.9)
Completed 24-week 
follow up
97 (67.8) 24 (68.6) 215 (75.4) 19 (65.5) 556 (68.2) 121 (61.1)
HCV genotype non-1 – – – – N=1149 N=216
Completed 12-week 
treatment
1089 (94.8) 202 (93.5)
Completed 24-week 
follow up
834 (72.6) 173 (80.1)
Previously treated N=149 N=58 N=536 N=57 N=348 N=82
Completed 12-week 
treatment
135 (90.6) 50 (86.2) 481 (89.7) 50 (87.7) 315 (90.5) 75 (91.5)
Completed 24-week 
follow up
95 (63.8) 36 (62.1) 395 (73.7) 35 (61.4) 200 (57.5) 37 (45.1)
PegIFN, peginterferon; RBV, ribavirin
Table 4 Reasons for withdrawal from treatment with peginterferon


















Treatment-naïve N=143 N=35 N=285 N=29 N=1964 N=414
Adverse event 20 (14.0) 1 (2.9) 40 (14.0) 3 (10.3) 111 (5.7) 37 (8.9)
Insufficient response 14 (9.8) 4 (11.4) 10 (3.5) 4 (13.8) 196 (10.0) 53 (12.8)
Good response 5 (3.5) 1 (2.9) 12 (4.2) 1 (3.4) 59 (3.0) 14 (3.4)
Refused treatment, 
withdrew consent, or 
did not cooperate
5 (3.5) 2 (5.7) 17 (6.0) 4 (13.8) 102 (5.2) 20 (4.8)
Failure to return 7 (4.9) 0 (0) 6 (2.1) 1 (3.4) 92 (4.7) 16 (3.9)
Administrative or 
other reason
1 (0.7) 0 (0) 2 (0.7) 0 (0) 11 (0.6) 4 (1.0)
Death 0 (0) 0 (0) 0 (0) 0 (0) 1 (<0.1) 1 (0.2)
Previously treated N=149 N=58 N=536 N=57 N=348 N=82
Adverse event 17 (11.4) 8 (13.8) 48 (9.0) 5 (8.8) 34 (9.8) 6 (7.3)
Insufficient response 36 (24.2) 12 (20.7) 85 (15.9) 6 (10.5) 76 (21.8) 23 (28.0)
Good response 1 (0.7) 1 (1.7) 24 (4.5) 4 (7.0) 4 (1.1) 0 (0)
Refused treatment, 
withdrew consent, or 
did not cooperate
2 (1.3) 3 (5.2) 21 (3.9) 2 (3.5) 22 (6.3) 3 (3.7)
Failure to return 4 (2.7) 1 (1.7) 13 (2.4) 5 (8.8) 15 (4.3) 3 (3.7)
Administrative or 
other reason
1 (0.7) 1 (1.7) 11 (2.1) 0 (0) 2 (0.6) 2 (2.4)
Death 0 (0) 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0)
PegIFN, peginterferon; RBV, ribavirin
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VR and safety in patients receiving dual therapy
Among treatment-naïve patients assigned to dual therapy 
with peginterferon alfa-2a/ribavirin and peginterferon alfa-2b/
ribavirin, SVR12 rates were 49.2% and 41.9%, respectively, in 
patients with G1 infection, 75.7% and 83.3% in patients with 
G2 infection, 65.9% and 65.9% in patients with G3 infection, 
and 49.7% and 51.1% in patients with G4 infection (Table 8). 
SVR12 rates are shown by HCV genotype and baseline 
characteristic in Table 9.
Among previously treated patients assigned to dual therapy 
with peginterferon alfa-2a/ribavirin and peginterferon alfa-2b/
ribavirin, overall SVR12 rates were 35.6% (124/348) and 25.6% 
(21/82), respectively.
The overall safety profile of dual therapy is presented in 
Table  10. Among patients assigned to peginterferon alfa-2a/
ribavirin and peginterferon alfa-2b/ribavirin, the incidence of 
AEs was 60.3% and 65.7% respectively, and the incidence of 
SAEs was 6.4% and 6.7%, respectively. The most commonly 
reported AE was anemia (in 19.7% and 28.6% of patients, 
respectively). Safety-related dosage modifications were required 
more frequently for ribavirin than for the peginterferon alfa 
component of the respective regimens and the most frequently 
cited reason for ribavirin dose reductions was anemia (in 
13.6% and 20.4% of patients assigned to peginterferon alfa-2a/
ribavirin and peginterferon alfa-2b/ribavirin, respectively) 
(Table 10).
Hepatic failure was reported as an SAE in three patients 
(two recipients of peginterferon alfa-2a and 1 recipient of 
peginterferon alfa-2b). Infections were reported as SAEs 
in 35 of 2312  (1.5%) patients assigned peginterferon alfa-
2a plus ribavirin and in 8 of 496  (1.6%) patients assigned to 
peginterferon alfa-2b plus ribavirin. A  total of nine patients 
assigned to dual therapy died, including 6 deaths in patients 
treated with peginterferon alfa-2a/ribavirin and 3 deaths 
in patients treated with peginterferon alfa-2b/ribavirin. All 
were unrelated to treatment in the opinion of the investigator, 
two were considered to be related to CHC (septic shock 
in a patient treated with peginterferon alfa-2a/ribavirin, 
and gastrointestinal hemorrhage in a patient treated with 
peginterferon alfa-2b/ribavirin), and for two patients no 
assessment of the relationship to CHC was provided.
Discussion
With the advent of second-generation DAAs, telaprevir 
and boceprevir have been withdrawn from the US market 
and PI-based triple therapy and dual peginterferon alfa/
Figure 2 SVR12 and relapse rates for patients receiving boceprevir- and telaprevir-based triple therapy. (A) SVR12 rates in treatment- naïve patients 
including 95% confidence intervals. (B) Relapse rates in treatment-naïve patients including 95% confidence intervals. (C) SVR12 rates in previously 
treated patients including 95% confidence intervals. (D) Relapse rates in previously treated patients including 95% confidence intervals
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ribavirin therapy are no longer recommended in treatment 
guidelines as a preferred treatment for patients infected with 
HCV G1 [10-12]. However, availability and cost restrictions 
mean that peginterferon-based regimens may continue in 
some countries, as is explicitly recognized by the European 
and Asian guidelines [11,12]. It therefore remains important 
to understand the efficacy and safety of peginterferon-based 
regimens in real-world settings, and the PegBase observational 
study provides data to this end.
The efficacy of first-generation PI-based triple therapy 
in PegBase was somewhat lower than that reported in phase 
III studies. The range of SVR12 rates achieved in treatment-
naïve patients with boceprevir-based triple therapy in the 
PegBase study (57-63%) overlaps with that obtained in the 
phase III trial (SPRINT-2, 63-66%) [7]. SVR12 rates achieved 
with telaprevir-based triple therapy in PegBase (59-65%) 
are below those observed with the approved regimen in 
ADVANCE (75%) [6] and ILLUMINATE (72%) [14]. These 
results are likely to be a reflection of differences between the 
highly restrictive criteria used to select patients for registration 
studies, the heterogeneous characteristics of patients 
encountered in routine clinical practice, and differences in the 
extent of monitoring and follow up between registration trials 
and real-world studies. For example, a higher proportion of 
patients with fibrosis assessments had transition to cirrhosis 
or had cirrhosis in PegBase (>30%) than in phase III trials of 
boceprevir (7-9%) or telaprevir (20%).
Likewise, in previously treated patients, overall SVR12 rates 
in PegBase were 44-48% in patients assigned to boceprevir-based 
triple therapy, compared with 59-66% in RESPOND-2 [8], 56-60% 
in patients assigned to telaprevir-based triple therapy and 
64% with the approved regimen in REALIZE [9]. Responses 
in previously treated patients are largely a reflection of the 
type of prior therapy, for example, interferon monotherapy or 
combination therapy with ribavirin, and the nature of the prior 
response to interferon-based therapy, with generally higher 
SVR rates in relapsers than in non-responders [15-17]. In 
RESPOND-2, approximately two-thirds of patients had a prior 
relapse and approximately one-third of patients had a prior 
non-response to peginterferon-based therapy [8]. Likewise, 
more than half of the patients in REALIZE (53%) had a previous 
relapse and 28% had a previous non-response to peginterferon-
based therapy [9]. In contrast, almost half of the previously 
treated patients enrolled in the present study were prior non-
responders, while only one-third of them had experienced a 
prior relapse. In addition, some previously treated patients had 
received conventional interferon monotherapy or peginterferon 
monotherapy. Thus, differences in response rates between 
Table 5 Virological response (VR), relapse and breakthrough rates – triple therapy









Treatment-naïve N=143 N=35 N=285 N=29
eRVR 67 (46.9; 38.5-55.4) 15 (42.9; 26.3-60.6) 122 (42.8; 37.0-48.8) 11 (37.9; 20.7-57.7)
EoT VR 103 (72.0; 63.9-79.2) 29 (82.9; 66.4-93.4) 228 (80.0; 74.9-840.5) 19 (65.5; 45.7-82.1)
SVR12 81 (56.6; 48.1-64.9) 22 (62.9; 44.9-78.5) 186 (65.3; 59.4-70.8) 17 (58.6; 38.9-76.5)
SVR24 75 (52.4; 43.9-60.9) 20 (57.1; 39.4-73.7) 169 (59.3; 53.3-65.1) 15 (51.7; 32.5-70.6)
Relapse 13/92 (14.1; 7.7-23.0) 5/27 (18.5; 6.3-38.1) 34/216 (15.7; 11.2-21.3) 1/18 (5.6; 0.1-27.3)
Breakthrough/rebound 11/134 (8.2; 4.2-14.2) 5/35 (14.3; 4.8-30.3) 22/272 (8.1; 5.1-12.0) 6/26 (23.1; 9.0-43.6)
Previously treated N=149 N=58 N=536 N=57
eRVR* 43 (28.9; 21.7-36.8) 15 (25.9; 15.3-39.0) 252 (47.0; 42.7-51.3) 30 (52.6; 39.0-66.0)
EoT VR 93 (62.4; 54.1-70.2) 38 (65.5; 51.9-77.5) 387 (72.2; 68.2-76.0) 38 (66.7; 52.9-78.6)
SVR12 65 (43.6; 35.5-52.0) 28 (48.3; 35.0-61.8) 323 (60.3; 56.0-64.4) 32 (56.1; 42.4-69.3)
SVR24 61 (40.9; 33.0-49.3) 27 (46.6; 33.3-60.1) 305 (56.9; 52.6-61.1) 26 (45.6; 32.4-59.3)
Relapse 25/89 (28.1; 19.1-38.6) 8/36 (22.2; 10.1-39.2) 46/365 (12.6; 9.4-16.5) 3/35 (8.6; 1.8-23.1)
Breakthrough/rebound 13/141 (9.2; 5.0-15.3) 9/53 (17.0; 8.1-29.8) 96/513 (18.7; 15.4-22.4) 10/48 (20.8; 10.5-35.0)
VR was defined as undetectable HCV RNA as assessed by a test with lower limit of detection ≤50 IU/mL, *eRVR was defined differently for patients receiving 
telaprevir (VR at weeks 4 and 12) and boceprevir (VR at weeks 8 and 24), Relapse was defined as non-response at the last HCV RNA assessment during the 
treatment-free follow-up period in patients with an EoT response. Patients were included in the calculation of relapse if they had an EoT response and an 
available HCV RNA measurement for SVR12 or an earlier follow-up assessment showing non-response during the treatment-free follow-up period (i.e., 
patients lost to follow up after EoT were not included in the calculation of relapse), Breakthrough/rebound was defined as non-response during the treatment 
period in patients with a previous response or increase in HCV RNA by ≥1 log10 during the treatment period versus the lowest value previously recorded 
during the treatment period. Patients were included in the calculation of breakthrough/rebound if they had ≥2 HCV RNA measurements during treatment 
(which could include imputation of EoT response)  
CI, confidence interval; EoT, end of treatment; eRVR, extended rapid virological response; PegIFN, peginterferon; RBV, ribavirin; SVR12, sustained virological 
response at least 12 weeks after the end of treatment (≥70 days after day of last dose); SVR24, sustained virological response at least 24 weeks after end of treatment 
(≥140 days after day of last dose)
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Table 6 Subgroup analysis by baseline characteristics of SVR12 in HCV G1 patients receiving triple therapy









Treatment-naïve N=143 N=35 N=285 N=29
Overall 81 (56.6) 22 (62.9) 186 (65.3) 17 (58.6)
Fibrosis status
Cirrhosis 24/55 (43.6) 6/12 (50.0) 53/98 (54.1) 10/18 (55.6)
No cirrhosis 57/88 (64.8) 16/23 (69.6) 133/187 (71.1) 7/11 (63.6)
IL28B rs12979860 host genotype*
CC 18/25 (72.0) 4/5 (80.0) 26/29 (89.7) 2/3 (66.7)
CT 22/39 (56.4) 6/8 (75.0) 51/82 (62.2) 7/12 (58.3)
TT 10/16 (62.5) 0/2 (0.0) 22/32 (68.8) 1/4 (25.0)
Unknown 31/63 (49.2) 12/20 (60.0) 87/142 (61.3) 7/10 (70.0)
HCV RNA, IU/mL
≤400,000 15/32 (46.9) 6/7 (85.7) 51/73 (69.9) 6/9 (66.7)
>400,000 66/111 (59.5) 15/27 (55.6) 135/212 (63.7) 11/20 (55.0)
Missing – 1/1 (100) – –
Previously treated N=149 N=58 N=536 N=57
Overall 65 (43.6) 28 (48.3) 323 (60.3) 32 (56.1)
Fibrosis status
Cirrhosis 27/83 (32.5) 12/29 (41.4) 124/243 (51.0) 14/25 (56.0)
No cirrhosis 38/66 (57.6) 16/29 (55.2) 199/293 (67.9) 18/32 (56.3)
IL28B rs12979860 host genotype*
CC 4/10 (40.0) 4/5 (80.0) 33/43 (76.7) 3/5 (60.0)
CT 24/51 (47.1) 11/25 (44.0) 102/179 (57.0) 15/27 (55.6)
TT 7/21 (33.3) 4/7 (57.1) 36/65 (55.4) 4/10 (40.0)
Unknown 30/67 (44.8) 9/21 (42.9) 151/248 (60.9) 10/15 (66.7)
HCV RNA, IU/mL
≤400,000 19/36 (52.8) 8/14 (57.1) 85/117 (72.6) 12/16 (75.0)
>400,000 46/113 (40.7) 20/44 (45.5) 236/417 (56.6) 20/41 (48.8)
Missing – – 2/2 (100.0) –
Prior response, n (%)
Relapse 30/44 (68.2) 13/19 (68.4) 140/177 (79.1) 14/27 (51.9)
Breakthrough 1/5 (20.0) 2/3 (66.7) 22/37 (59.5) 1/2 (50.0)
Non-response 29/82 (35.4) 9/28 (32.1) 117/248 (47.2) 11/17 (64.7)
Other 4/17 (23.5) 3/7 (42.9) 39/68 (57.4) 6/10 (60.0)
Prior response unknown 1/1 (100) 1/1 (100) 5/6 (83.3) 0/1 (0)
SVR12 = percentage of patients with undetectable HCV RNA (to a test with lower limit of detection ≤50 IU/mL) at 12 weeks after completion of the treatment 
period (at least 70 days after day of last treatment), *Host genotype was unknown in 235 treatment-naïve patients and 351 Previously treated patients. One 
previously treated patient was negative for rs12979860 
HCV, hepatitis C virus; PegIFN, peginterferon; RBV, ribavirin; SVR, sustained virological response
PegBase and phase III studies reflect not only differences in 
baseline characteristics, but also differences in the proportion of 
patients with prior relapse or non-response and in the intensity 
of the previous treatment regimen.
Predictors of good VR include absence of cirrhosis, 
homozygosity for the IL28B rs12979860 C allele and low viral 
load [18]. In the PegBase study, patients without transition 
to cirrhosis or cirrhosis had better virological outcomes than 
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N=292 N=93 N=821 N=86
Patients with ≥1 AE, n (%) 224 (76.7) 82 (88.2) 745 (90.7) 75 (87.2)
Patients with ≥1 SAE, n (%) 43 (14.7) 9 (9.7) 163 (19.9) 4 (4.7)
Death 2 (0.7) 1 (1.1) 8 (1.0) 0
Incidence of individual AEs*, n (%)
Anemia, n (%) 120 (41.1) 45 (48.4) 398 (48.5) 44 (51.2)
Neutropenia 39 (13.4) 25 (26.9) 86 (10.5) 24 (27.9)
Asthenia 53 (18.2) 23 (24.7) 246 (30.0) 9 (10.5)
Pruritus 37 (12.7) 16 (17.2) 240 (29.2) 10 (11.6)
Thrombocytopenia 33 (11.3) 6 (6.5) 98 (11.9) 23 (26.7)
Leukopenia 10 (3.4) 6 (6.5) 60 (7.3) 31 (36.0)
Nausea 36 (12.3) 24 (25.8) 135 (16.4) 11 (12.8)
Fatigue 68 (23.3) 23 (24.7) 172 (21.0) 13 (15.1)
Rash 26 (8.9) 9 (9.7) 161 (19.6) 10 (11.6)
Influenza-like illness 31 (10.6) 17 (18.3) 97 (11.8) 7 (8.1)
Decreased appetite 25 (8.6) 16 (17.2) 118 (14.4) 8 (9.3)
Headache 33 (11.3) 15 (16.1) 94 (11.4) 5 (5.8)
Dysgeusia 33 (11.3) 14 (15.1) 40 (4.9) 1 (1.2)
Hemoglobin increased 1 (0.3) 0 16 (1.9) 13 (15.1)
Insomnia 18 (6.2) 7 (7.5) 100 (12.2) 4 (4.7)
Diarrhea 17 (5.8) 11 (11.8) 79 (9.6) 5 (5.8)
Pyrexia 14 (4.8) 11 (11.8) 36 (4.4) 4 (4.7)
Alopecia 14 (4.8) 10 (10.8) 51 (6.2) 2 (2.3)
Cough 23 (7.9) 10 (10.8) 72 (8.8) 1 (1.2)
Dry skin 22 (7.5) 10 (10.8) 66 (8.0) 3 (3.5)
Peginterferon dose modification‡, n (%) 49 (16.8) 18 (19.4) 104 (12.7) 9 (10.5)
Neutropenia 31 (10.6) 10 (10.8) 24 (2.9) 5 (5.8)
Thrombocytopenia 9 (3.1) 1 (1.1) 37 (4.5) 3 (3.5)
Anemia 3 (1.0) 2 (2.2) 14 (1.7) 0
Other  8 (2.7) 7 (7.5) 36 (4.4) 1 (1.2)
Ribavirin dose modification‡, n (%) 125 (42.8) 40 (43.0) 381 (46.4) 31 (36.0)
Anemia 115 (39.4) 37 (39.8) 336 (40.9) 29 (33.7)
Other 14 (4.8)  8 (8.6) 75 (9.1) 2 (2.3)
Laboratory abnormalities, lowest value after BL, n (%)
Hemoglobin <100 g/L 121 (41.6) 36 (39.1) 357 (43.8) 36 (43.4)
Platelets <100 × 109/L 145 (50.0) 42 (45.7) 400 (49.1) 31 (37.3)
Neutrophils <2.0 × 109/L 262 (90.7) 85 (92.4) 707 (87.4) 60 (73.2)
*Incidence ≥10% in at least one of the treatment groups, †Total number of deaths regardless of relation to treatment in the opinion of the investigator, ‡Because 
of adverse event or laboratory abnormality  
AE, adverse event; BL, baseline; HCV, hepatitis C virus; PegIFN, peginterferon; RBV, ribavirin; SAE, serious adverse event
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patients with transition to cirrhosis or cirrhosis, and higher 
response rates were seen in patients homozygous for the IL28B 
rs12979860 C allele than in patients heterozygous for the C 
and T alleles or in patients homozygous for the T allele. There 
was little difference in treatment response between treatment-
naïve patients with high or low viral loads; however, previously 
treated patients with low viral loads responded better than 
those with high viral loads.
The spectrum of AEs observed in PegBase is consistent with 
that reported in phase III studies of boceprevir- and telaprevir-
based triple therapy [6-9]. The lower incidence of certain 
AEs, such as rash, in PegBase (approximately 16%) than in 
phase III trials (>30%) is possibly a reflection of closer patient 
monitoring in registration studies.
The efficacy of first-generation PI-based triple therapy in 
PegBase is consistent with other “real-world” studies in that 
they also report lower SVR rates than those in registration 
studies [19-22]. For example, in the German PAN cohort 
study [23], SVR12 rates of 55% (boceprevir) and 63% 
(telaprevir) were obtained in treatment-naïve patients and 
51% (boceprevir) and 68% (telaprevir) in previously treated 
patients. The Kaiser Permanente Medical Care Program in 
Northern California reported SVR rates of 53% and 56% with 
boceprevir- and telaprevir-based triple therapy [21]. SVR rates 
were also lower in previously treated patients with cirrhosis 
who received first-generation triple therapy in the French 
CUPIC study [20]. The CUPIC study is noteworthy in that it 
reported comparatively high rates of SAEs (50%) and hepatic 
decompensation (8%), and deaths were associated with severe 
infections, perhaps as a result of the inclusion of patients 
with contraindications for the triple-therapy regimens. The 
lower rates of SAEs, hepatic failure and the absence of a link 
between serious infection and deaths in PegBase suggests that 
contraindications were observed when selecting patients for 
PegBase.
The efficacy and safety profile of dual peginterferon alfa/
ribavirin therapy in PegBase is similar to that reported in 
previous randomized controlled studies and in other large 
real-world studies [24-27]. The place of dual therapy in the 
treatment of CHC has continued to diminish since the PegBase 
study was initiated. In particular, dual therapy is no longer 
suitable in patients with access to DAAs, because of the lower 
efficacy and longer duration of treatment [10-12].
No firm conclusions can be drawn regarding the 
comparative efficacy or safety of boceprevir and telaprevir or 
of peginterferon alfa-2a and peginterferon alfa-2b on the basis 
of this study, as patients were not randomized and between-
group differences may be due to selection bias. Moreover, the 
dose and duration of treatment were left to the discretion of 
the investigators. Patient assessments were performed in local 
laboratories, which means that certain baseline characteristics, 
for example, IL28B genotype, were not known for all patients, 
and that the sensitivity of assays used to determine SVR varied 
between sites.
In conclusion, the overall efficacy of first-generation PI-based 
triple-therapy regimens in this real-world study was similar to 
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lower than that reported in registration trials, whilst the safety 
profile of triple therapy was broadly comparable to that in phase 
III clinical trials. Efficacy and safety with dual-therapy regimens 
were comparable to previous real-world studies.
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Table 9 Sustained virological response at 12 weeks after the end of treatment in treatment-naïve patients with HCV mono-infection receiving 
dual therapy by baseline characteristics
Baseline 
characteristic
Percentage of patients with SVR12 n/N (%)












































































































































SVR12 = percentage of patients with response at least 12 weeks after completion of the treatment period, i.e., HCV RNA <50 IU/mL at least 70 days after day of 
last dose. Response: HCV RNA <50 IU/mL  
HCV, hepatitis C virus; PegIFN, peginterferon; RBV, ribavirin; SVR, sustained virological response
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Table 10 Safety outcomes in treatment-naïve and previously treated 
patients with HCV mono-infection (any genotype) receiving dual 
therapy 






Patients with ≥1 AE, n (%) 1393 (60.3) 326 (65.7)
Patients with ≥1 SAE, n (%) 148 (6.4) 33 (6.7)
Deaths†, n (%) 6 (0.3) 3 (0.6)
Incidence of individual AEs*, 
n (%)
Anemia 456 (19.7) 142 (28.6)
Neutropenia 270 (11.7) 65 (13.1)
Asthenia 237 (10.3) 72 (14.5)
Fatigue 244 (10.6) 53 (10.7)
Pruritus 160 (6.9) 55 (11.1)
Peginterferon dose 
modification‡, n (%)
243 (10.5) 65 (13.1)
Neutropenia 138 (6.0) 22 (4.4)
Thrombocytopenia 46 (2.0) 9 (1.8)
Anemia 14 (0.6) 7 (1.4)
Other 71 (3.1) 34 (6.9)
Ribavirin dose modification‡, 
n (%)
384 (16.6) 120 (24.2)
Anemia 315 (13.6) 101 (20.4)
Other 95 (4.1) 22 (4.4)
Laboratory abnormalities, 
lowest values after BL, n (%)
Hemoglobin <100 g/L 417 (18.4) 100 (20.7)
Platelets <100 × 109/L 716 (31.6) 110 (22.8)
Neutrophils <2.0 × 109/L 1914 (86.1) 420 (87.9)
*Incidence ≥10% in one or both treatment groups, †Total number of deaths 
regardless of relation to treatment in the opinion of the investigator, ‡Because 
of adverse event or laboratory abnormality 
AE, adverse event; BL, baseline; HCV, hepatitis C virus; PegIFN, peginterferon; 
RBV, ribavirin; SAE, serious adverse event
Annals of Gastroenterology 30 
342 A. Mangia et al
References
1. World Health Organization (WHO). Guidelines for the screening, 
care and treatment of persons with hepatitis C infection. April 2014. 
Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-
guidelines/en/. Last accessed: 3 March 2017.
2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and 
prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87.
3. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific 
fibrosis progression rates in chronic hepatitis C virus infection: a 
meta-analysis and meta-regression. Hepatology 2008;48:418-431.
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology 
and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
5. Cooke GS, Lemoine M, Thursz M, et al. Viral hepatitis and the Global 
Burden of Disease: a need to regroup. J Viral Hepat 2013;20:600-601.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study 
Team. Telaprevir for previously untreated chronic hepatitis C virus 
infection. N Engl J Med 2011;364:2405-2416.
7. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. 
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl 
J Med 2011;364:1195-1206.
8. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 
Investigators. Boceprevir for previously treated chronic HCV 
genotype 1 infection. N Engl J Med 2011;364:1207-1217.
9. Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir 
for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
10. American Association for the Study of Liver Diseases 
(AASLD) & Infectious Diseases Society of America (IDSA). 
HCV Guidance: Recommendations for testing, managing, 
and treating hepatitis  C. Updated 2016. Available at: 
http://www.hcvguidelines.org/fullreport. Accessed June 2016.
11. European Association for Study of Liver. EASL Recommendations 
on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236.
12. Omata M, Kanda T, Wei L, et al. APASL consensus statements 
and recommendation on treatment of hepatitis C. Hepatol Int 
2016;10:702-726.
13. European Association for Study of Liver. EASL Clinical Practice 
Guidelines: management of hepatitis C virus infection. J  Hepatol 
2014;60:392-420.
14. Sherman KE, Flamm SL, Afdhal NH, et al; ILLUMINATE Study 
Team. Response-guided telaprevir combination treatment for 
hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
15. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al; Hepatitis C 
Antiviral Long-Term Treatment Against Cirrhosis Trial Group. 
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis 
C who have failed prior treatment. Gastroenterology 2004;126:1015-
1023; discussion 947.
16. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of 
pegylated interferon alpha-2b plus ribavirin in the retreatment of 
chronic hepatitis C. Am J Gastroenterol 2005;100:2453-2462.
17. Poynard T, Colombo M, Bruix J, et al; Epic Study Group. Peginterferon 
alfa-2b and ribavirin: effective in patients with hepatitis C who failed 
interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618-
1628.e2.
18. Poordad F, Bronowicki JP, Gordon SC, et al; SPRINT-2 and 
RESPOND-2 Investigators. Factors that predict response of patients 
with hepatitis C virus infection to boceprevir. Gastroenterology 
2012;143:608-618.e1-e5.
19. Hézode C, Fontaine H, Dorival C, et al; CUPIC Study Group. Triple 
therapy in treatment-experienced patients with HCV-cirrhosis in a 
multicentre cohort of the French Early Access Programme (ANRS 
CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434-441.
20. Hézode C, Fontaine H, Dorival C, et al; CUPIC Study Group. 
Effectiveness of telaprevir or boceprevir in treatment-experienced 
patients with HCV genotype  1 infection and cirrhosis. 
Gastroenterology 2014;147:132-142.e4.
21. Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM. 
Effectiveness of telaprevir and boceprevir triple therapy for patients 
with hepatitis C virus infection in a large integrated care setting. Dig 
Dis Sci 2014;59:3043-3052.
22. Gordon SC, Muir AJ, Lim JK, et al; HCV-TARGET study group. Safety 
profile of boceprevir and telaprevir in chronic hepatitis C: real world 
experience from HCV-TARGET. J Hepatol 2015;62:286-293.
23. Mauss S, Böker K, Buggisch P, et al. Real-life experience with first 
generation HCV protease inhibitor therapy in Germany: The 
prospective, non-interventional PAN cohort. Z  Gastroenterol 
2015;53:644-654.
24. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b 
plus ribavirin compared with interferon alfa-2b plus ribavirin for 
initial treatment of chronic hepatitis C: a randomised trial. Lancet 
2001;358:958-965.
25. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a 
plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 
2002;347:975-982.
26. Hadziyannis SJ, Sette H Jr, Morgan TR, et al; PEGASYS International 
Study Group. Peginterferon-alpha2a and ribavirin combination 
therapy in chronic hepatitis C: a randomized study of treatment 
duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
27. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic 
response rates in rapid virologic response patients in the large real-
world PROPHESYS cohort confirm results from randomized clinical 
trials. Hepatology 2012;56:2039-2050.
Summary Box
What is already known:
•	 When	 added	 to	 peginterferon	 alfa/ribavirin,	 the	
first direct-acting antiviral agents for chronic 
hepatitis C (boceprevir and telaprevir) increased 
sustained virological response (SVR) rates in 
genotype 1 patients and reduced the duration of 
treatment required to maximize SVR rates
•	 First-generation	 protease	 inhibitor	 (PI)-based	
triple therapy is associated with a higher adverse 
event burden than dual peginterferon alfa/ribavirin 
therapy
•	 SVR	 rates	 are	 higher	 in	 treatment-naïve	 patients	
than in previously treated patients
•	 Previous	 cohort	 studies	 of	 first-generation	
PI-based triple therapy reported lower SVR rates 
than those achieved in registration studies
What the new findings are:
•	 The	 results	 of	 this	 large	 real-world	 observational	
trial of boceprevir- and telaprevir-based triple 
therapy in a heterogeneous “real-world” population 
are consistent with previous, smaller cohort studies 
that have reported somewhat lower SVR rates than 
those obtained in phase III registration studies
•	 The	 tolerability	 profile	 of	 boceprevir-	 and	
telaprevir-based triple therapy in a real-world 
setting is similar to that reported in registration 
studies
•	 When	 triple	 therapy	 is	 prescribed	 in	 accordance	
with local standards of practice, as recommended 
in this trial, and the approved label, as in the present 
study, the incidence of hepatic decompensation 
and death is low
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Supplemental Table 1 Definition of the core population
Adult male or female patients with chronic hepatitis C (CHC), hepatitis C virus (HCV) mono-infection with known HCV genotype and known 








CHC was not confirmed (i.e., no positive baseline HCV RNA record, or acute hepatitis C)




Hepatitis B virus coinfection
HIV coinfection or unknown HIV infection status
Infection with a non-1 HCV genotype and receipt of boceprevir- or telaprevir-based triple combination therapy
Treatment with a combination other than the six described above
Missing final confirmation of the data by the principal investigator
Supplemental Table 2 Reasons for exclusion of treated patients from 
the core population (safety population)




No treatment or treatment other than Peg-IFN 
alfa-2a + RBV or Peg-IFN alfa-2b + RBV or one 
of these two regimens plus either boceprevir or 
telaprevir
23
Not HCV RNA-positive at baseline 14
Triple therapy administered to non-genotype 1 
patient
29
No final confirmation by principal investigator 26
Non-adult CHC patient receiving dual or triple 
therapy
1
HCV genotype missing 9




Response at baseline 6
End-stage renal disease 4
Major organ transplantation 3
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